Market Overview

Stifel Doubles Down On MEI Pharma, Considers ME-401 'Best-In-Class'

Stifel Doubles Down On MEI Pharma, Considers ME-401 'Best-In-Class'

MEI Pharma Inc (NASDAQ: MEIP) is down 31.5 percent from its one-year high struck after the release of preliminary data for ME-401.

Stifel Nicolaus considers the decline a stake-building opportunity.

The Analyst 

Analyst Stephen Willey upgraded MEI from Hold to Buy and raised the price target from $2.50 to $7.

The Thesis

ME-401 justifies a bullish stance, Willey said: the candidate demonstrated a 90-percent overall response rate in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. (See Willey's track record here.) 

“We believe year-end 2018 updated Phase 1B ME-401 data is likely to solidify ME-401 as a best-in-class compound and believe the planned year-end 2018 initiation of a pivotal single-arm/monotherapy trial in third-line follicular lymphoma should provide a clear runway to commercialization with minimal underlying development/regulatory risk,” the analyst said. 

The drug is considered a market share threat to existing rivals, including Gilead Sciences, Inc. (NASDAQ: GILD)’s Zydelig/idelalisib or Bayer’s Aliqopa/copanlisib. Stifel estimates peak U.S. sales in R/R FL beyond $300 million, which would contribute $5 per share in discounted cash flow.

At the same time, MEI’s CDK9 inhibitor voruciclib is a source of long-term optionality in potential combination therapies with venetoclax, Willey said. 

Stifel is less optimistic for pracinostat in acute myeloid leukemia and myelodysplastic syndromes, but considers the drug less critical to MEI’s story. Encouraging data could nonetheless drive upside, the analyst said. 

Price Action

MEI Pharma shares were trading up 5.41 percent to $3.70 at the time of publication Friday morning. 

Related Links:

GlaxoSmithKline, 23andMe Partner On DNA Data In Drug Development

With Positive Phase 2b Results In Hand, resTORbio CEO Sees Path To 2020 NDA

Latest Ratings for MEIP

May 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy
Feb 2019BTIG ResearchInitiates Coverage OnBuy
Dec 2018H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for MEIP
View the Latest Analyst Ratings


Related Articles (MEIP)

View Comments and Join the Discussion!

Posted-In: Stephen Willey Stifel NicolausAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at